Frequency of pharmacogenomic variation and medication exposures among participants in the All of Us Research Program
Andrew Haddad, Aparna Radhakrishnan, Sean R. McGee, Joshua D. Smith, Jason H. Karnes, Eric Venner, Marsha M. Wheeler, Karynne Patterson, Kimberly Walker, Divya Kalra, Sara E. Kalla, Qiaoyan Wang, Kathleen Polkowski, Richard A. Gibbs, Gail Pairitz Jarvik, Janeth I. Sanchez, Anjene Musick Addington, Andrea H. Ramirez, Joshua C. Denny, Philip E. Empey, Dmitry Abramov, Brian Ahmedani, Habib Ahsan, Hoda Anton-Culver, Maria Argos, Dave W. Arnold, Brisa Aschebook-Kilfoy, Katie Baca-Motes, Catherine Balthazar, Laura Bartlett, Gillian Bartlett‐Esquilant, Melissa Basford, Leland Baskin, Mark Begale, Eric Boerwinkle, Ingrid Bonilla-Mercado, Alexander Borowsky, Amaryllis Silva Boschetti, Matthew Breeden, Brad Bryan, Jessica Burke, Elizabeth Burnside, Lisa Cadmus-Bertram, Librada Callender, Roberta Carlin, Olveen Carrasquillo, Suchitra Chandrasekaran, Alexander Charney, Mine Cicek, Cheryl Clark and 10 more
Peer-reviewed journalReal-world use
In the authors' words
This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.
Main result
Importantly, we report thousands of previously unrecognized pharmacogene variants and hundreds of alleles and predicted phenotypes that deviate from known frequencies across populations or were previously unreported, especially in the Americas and African ancestry groups.
These findings establish the first human safety and pharmacokinetic profile of a novel, orally administered actinide chelator and support further clinical evaluation of HOPO 14-1 as a countermeasure for internal radionuclide and heavy metal contamination.
Sascha N. Goonewardena, Laura Atleski, Deborah I. Bunin and 4 more — JAMA
Peer-reviewed journalClaims a big stepReal-world use
Here we describe a novel therapeutic modality, domain-alteration chimeras (DALTACs), that rewire endogenous protein complexes by enforcing non-native domain–domain interactions.
Jie Luo, Jianzhang Yang, Jean Ching-Yi Tien and 26 more — Nature
Peer-reviewed journalBold claims, read criticallyClaims a big stepReal-world use
By screening a US Food and Drug Administration–approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism.
Wenyu Fu, Ronghan Liu, Jin Wo and 13 more — Science Translational Medicine
We present DrugCon, a large language model (LLM)-based framework that extracts study conclusions from RCT abstracts, links these claims when they concern the same drug-disease association, detects contradictions with counterfactual reasoning, and explains them using a taxonomy of ten study-level factors such as population, dosage, and outcome measures.